Generic Ojjaara Availability
Last updated on Mar 13, 2025.
Ojjaara is a brand name of momelotinib, approved by the FDA in the following formulation(s):
OJJAARA (momelotinib dihydrochloride - tablet;oral)
-
Manufacturer: GLAXOSMITHKLINE
Approval date: September 15, 2023
Strength(s): EQ 100MG BASE [RLD], EQ 150MG BASE [RLD], EQ 200MG BASE [RLD]
Has a generic version of Ojjaara been approved?
No. There is currently no therapeutically equivalent version of Ojjaara available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ojjaara. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,963,962
Patent expiration dates:
- December 2, 2040✓
- December 2, 2040
-
Phenyl amino pyrimidine compounds and uses thereof
Patent 8,486,941
Issued: July 16, 2013
Inventor(s): Burns Christopher John & Donohue Andrew Craig & Feutrill John Thomas & Nguyen Thao Lien Thi & Wilks Andrew Frederick & Zeng Jun
Assignee(s): YM Biosciences Australia Pty LtdThe present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
Patent expiration dates:
- January 3, 2030✓✓✓
- January 3, 2030
-
(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Patent 9,809,559
Issued: November 7, 2017
Inventor(s): Brown Brandon H. & Carra Ernest A. & Hemenway Jeffrey N. & Morrison Henry & Reynolds Troy & Shi Bing & Stefanidis Dimitrios & Wang Fang & Warr Matthew Robert & Whitney James Andrew & Xin Yan
Assignee(s): GILEAD SCIENCES, INC.The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Patent expiration dates:
- June 11, 2035✓
- June 11, 2035
-
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Patent RE48285
Issued: October 27, 2020
Inventor(s): Brown Brandon H. & Carra Ernest A. & Hemenway Jeffrey N. & Morrison Henry & Reynolds Troy & Shi Bing & Stefanidis Dimitrios & Wang Fang & Warr Matthew Robert & Whitney James Andrew & Xin Yan
Assignee(s): Sierra Oncology, Inc.The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Patent expiration dates:
- June 11, 2035✓✓✓
- June 11, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 15, 2028 - NEW CHEMICAL ENTITY
- September 15, 2030 - TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA
More about Ojjaara (momelotinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
